Clinical trials: Cervical Intraepithelial Neoplasia (CIN)
Cervical Intraepithelial Neoplasia, Cervical Cancer
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04704908
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 979 people
- Sponsor
- Jun Zhang
Cervical Dysplasia, Vulvar Dysplasia
OCT-AF Imaging of Pre-cancers of Vulva and Cervix
The multimodal imaging technology, OCT-AFI, will be used to image sites on the cervix, the endocervical canal and vulva. The imaging probe is small enough, it can be inserted into the endocervical canal for imaging.
- Conditions
- Cervical Dysplasia, Vulvar Dysplasia, Precancerous Lesions, Vulvar Cancer
- Trial name
- NCT03285841
- Testing
- OCT-AFI
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS)
Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer
This study compares how effective is the molecular screening (a blood test) using Pap smear as reference, that is, a comparison of these tests abilities to detect precursor lesions and cervical cancer among women of an open…
- Conditions
- I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS), III) Cervical Intraepithelial Neoplasia (CIN), CIN-1, CIN-2, CIN-3, IV) Low-grade Squamous Intraepithelial Lesion (LSIL)
- Trial name
- NCT07480902
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Stenosis Cervix
How to Avoid Cervical Stenosis After LEEP in High Grade Cervical Dysplasia?
Cervical stenosis may occur in up to 19% after conization. It is a cause of infertility and amenorrhea. This study will test a new device named DUDA Device ("Dispositivo Uterino para dilatar canal endocervical") placed just after…
- Trial name
- DUDA (NCT02500966)
- Testing
- DUDA device, LEEP
- Where
- Brazil
- Volunteers
- 265 people
- Sponsor
- Barretos Cancer Hospital
Cervical Intraepithelial Neoplasia, Cervical Cancer
DNA Methylation Biomarkers for Cervical Cancer Screening
The purpose of this prospective study is to evaluate whether DNA methylation can be applied in cervical cancer screening.
- Trial name
- NCT02605941
- Where
- Taiwan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- iStat Biomedical CO., Ltd.
Cervical Dysplasia
Effect of a Childcare Resource on Cervical Cancer Prevention
Aim 1: Determine the prevalence of unmet childcare needs among women with abnormal cervical cancer screening and establish the relevance of childcare as a social determinant of health in the context of cervical dysplasia.
- Trial name
- NCT06086054
- Testing
- Navigation and EMR referral to childcare facility
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cervical Dysplasia, Cervical Lesion
See and Treat in an Outpatient Setting in Women Above 45 Years With Cervical Dysplasia
The study will investigate if implementation of "see and treat" in the outpatient clinic can optimize the diagnosis, clinical follow-up and treatment of older women with positive cervical screening test.
- Conditions
- Cervical Dysplasia, Cervical Lesion, Cervix Disease
- Trial name
- NCT04298957
- Testing
- Cone biopsy
- Where
- 3 sites in Denmark
- Volunteers
- 109 people
- Sponsor
- University of Aarhus
Human Immunodeficiency Virus, Human Papillomavirus
Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya
The objective of this randomized, placebo-controlled trial is to evaluate whether intravaginal artesunate pessaries (vaginal inserts) can be used as adjuvant therapy following thermal ablation to improve Human papillomavirus…
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus, Cervical Precancer
- Trial name
- NCT06519994
- Testing
- Artesunate vaginal inserts
- Where
- Kenya
- Volunteers
- 120 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Papillomavirus Infections
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines.
- Trial name
- NCT00685412
- Testing
- VGX-3100
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections, p16 Protein
- Trial name
- NCT06439433
- Testing
- Aminolaevulinic acid (500-mg bottle), Aminolaevulinic acid (750-mg bottle)
- Where
- 5 sites in China
- Volunteers
- 119 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Cervical Intraepithelial Neoplasia, Cervical Cancer
The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
The primary objective of this study is to evaluate the durability of protection and immuno-persistence of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT05045755
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 1,339 people
- Sponsor
- Jun Zhang
Cervical Intraepithelial Neoplasia
Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1
This study looks at immediate treatment of a cervix with CIN 1 versus regular six-month follow-up with colposcopy and treatment if CIN 1 progresses.
- Trial name
- NCT00156026
- Testing
- loop electrosurgical excision procedure (LEEP)
- Where
- 10 sites in Brazil, Canada
- Volunteers
- 415 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)